Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
E S CasperM F Brennan

Abstract

To define the maximum-tolerated dose (MTD) of liposome-encapsulated doxorubicin (LED) when used every 2 weeks with granulocyte colony-stimulating factor (G-CSF) in patients with advanced soft tissue sarcoma. Doxorubicin encapsulated in egg phosphatidylcholine/cholesterol liposomes was given to patients with sarcoma in a disease-specific phase I trial. The initial dose was 75 mg/m2 with G-CSF 5 micrograms/kg. The MTD was defined as the highest dose that could be given every 2 weeks. Twenty-nine patients participated in this study. Major toxicities included myelosuppression, nausea and vomiting, fatigue, and mucositis. Eight patients were hospitalized for nadir fever. No cardiotoxicity was seen. The MTD was LED 105 mg/m2 with G-CSF 5 micrograms/kg. LED 120 mg/m2 resulted in tolerable, albeit prominent, acute toxicity, but did not permit recycling of therapy on day 15. Among 26 patients with soft tissue sarcoma, 23 had measurable disease, of whom three achieved a partial response (13%; 95% confidence interval, 2% to 34%). LED can be administered every 2 weeks at a dose of 105 mg/m2 with G-CSF support, which provides a dose-intensity of 52.5 mg/m2/wk. To exceed this intensity, the dose of LED that would have to be administered ever...Continue Reading

Citations

May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C L ShapiroD F Hayes
Nov 4, 2000·Expert Opinion on Investigational Drugs·S R Patel
Dec 12, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·D N WaterhouseM B Bally
Jul 14, 1999·Seminars in Surgical Oncology·S R Patel, R S Benjamin
Jun 3, 2011·Current Oncology Reports·Sherif S Morgan, Lee D Cranmer
Dec 22, 1998·Biochimica Et Biophysica Acta·X LiW R Perkins
Feb 15, 2001·American Journal of Otolaryngology·S G PatelJ P Shah
Jun 20, 1998·Seminars in Radiation Oncology·F Yuan
Mar 21, 2008·Journal of Pharmaceutical Sciences·Daryl C DrummondDmitri B Kirpotin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Massimo LopezSilvia Carpano
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M S GeorgiadisB E Johnson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
G A MastersE E Vokes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
E RowinskyR C Donehower
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Sandra M SwainS F Honig
© 2021 Meta ULC. All rights reserved